MetaVia Inc. (NASDAQ:MTVA) Short Interest Down 70.1% in June
by Danessa Lincoln · The Markets DailyMetaVia Inc. (NASDAQ:MTVA – Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 124,038 shares, a decline of 70.1% from the June 15th total of 414,844 shares. Based on an average daily trading volume, of 204,942 shares, the short-interest ratio is presently 0.6 days. Approximately 2.4% of the shares of the stock are short sold.
Hedge Funds Weigh In On MetaVia
A hedge fund recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Wall Street Zen upgraded MetaVia to a “sell” rating in a research report on Saturday, June 20th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of MetaVia in a research note on Friday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.00.
Get Our Latest Analysis on MetaVia
MetaVia Price Performance
MTVA traded up $0.05 during trading hours on Friday, reaching $1.78. The company’s stock had a trading volume of 129,086 shares, compared to its average volume of 193,318. The stock has a market cap of $9.18 million, a PE ratio of -0.34 and a beta of 0.97. MetaVia has a fifty-two week low of $0.97 and a fifty-two week high of $19.03. The business’s 50-day moving average is $1.90 and its 200-day moving average is $2.61.
MetaVia (NASDAQ:MTVA – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Analysts expect that MetaVia will post -2.78 EPS for the current year.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.